Rare
lephants
Screener
Toggle theme
Keros Therapeutics, Inc.
KROS
·
Healthcare, Drug Manufacturers - General, United States
Analysis
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Profit History
Profit Flow
Profit Margins
Returns on Capital
Profitability
›
Returns on Capital
Annual
Quarterly
Compare
←
5Y
10Y
MAX
→
Returns on Capital
Chart
Table
ROE
ROI
ROA
Fiscal Year
ROE
ROI
ROA
FY2024
-32.8%
-32.8%
-30.4%
FY2025
28.7%
28.7%
25.7%
Download CSV
